AR118881A1 - Composiciones de virus inactivado y formulaciones de vacuna contra el zika - Google Patents

Composiciones de virus inactivado y formulaciones de vacuna contra el zika

Info

Publication number
AR118881A1
AR118881A1 ARP200101302A ARP200101302A AR118881A1 AR 118881 A1 AR118881 A1 AR 118881A1 AR P200101302 A ARP200101302 A AR P200101302A AR P200101302 A ARP200101302 A AR P200101302A AR 118881 A1 AR118881 A1 AR 118881A1
Authority
AR
Argentina
Prior art keywords
vaccine formulations
inactivated virus
virus compositions
zika vaccine
pharmaceutically acceptable
Prior art date
Application number
ARP200101302A
Other languages
English (en)
Inventor
Michael Johnson
Sushma Kommareddy
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of AR118881A1 publication Critical patent/AR118881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente se refiere a una composición del virus líquido inactivado que comprende: un virus del Zika entero inactivado, al menos un tampón farmacéuticamente aceptable con una concentración de al menos aproximadamente 6,5 mM y opcionalmente un poliol, donde al menos dicho tampón farmacéuticamente aceptable no comprende iones de fosfato y vacunas derivadas de este.
ARP200101302A 2019-05-08 2020-05-07 Composiciones de virus inactivado y formulaciones de vacuna contra el zika AR118881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962845024P 2019-05-08 2019-05-08

Publications (1)

Publication Number Publication Date
AR118881A1 true AR118881A1 (es) 2021-11-10

Family

ID=70465537

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101302A AR118881A1 (es) 2019-05-08 2020-05-07 Composiciones de virus inactivado y formulaciones de vacuna contra el zika

Country Status (14)

Country Link
US (1) US20220211836A1 (es)
EP (1) EP3965811A1 (es)
JP (1) JP2022533550A (es)
KR (1) KR20220007077A (es)
CN (1) CN113939311A (es)
AR (1) AR118881A1 (es)
AU (1) AU2020269164B2 (es)
BR (1) BR112021019845A2 (es)
CA (1) CA3137652A1 (es)
IL (1) IL288002A (es)
MX (1) MX2021011913A (es)
SG (1) SG11202110975XA (es)
TW (1) TW202108168A (es)
WO (1) WO2020226831A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008652A2 (pt) 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
EP3322441A4 (en) * 2015-07-16 2018-12-19 Bharat Biotech International Limited Vaccine compositions
HRP20230273T1 (hr) * 2015-12-23 2023-04-28 Valneva Austria Gmbh Cjepivo protiv zika virusa
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
WO2017210215A1 (en) * 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
BR112020008652A2 (pt) * 2017-11-03 2020-11-10 Takeda Vaccines, Inc. vacinas e composições imunogênicas contra zika e métodos de uso das mesmas
AU2018375173B2 (en) * 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN108187036A (zh) * 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 一种寨卡病毒与乙脑病毒联合灭活疫苗

Also Published As

Publication number Publication date
TW202108168A (zh) 2021-03-01
WO2020226831A1 (en) 2020-11-12
EP3965811A1 (en) 2022-03-16
AU2020269164B2 (en) 2024-04-04
AU2020269164A1 (en) 2021-11-25
US20220211836A1 (en) 2022-07-07
IL288002A (en) 2022-01-01
JP2022533550A (ja) 2022-07-25
KR20220007077A (ko) 2022-01-18
BR112021019845A2 (pt) 2022-02-15
CN113939311A (zh) 2022-01-14
CA3137652A1 (en) 2020-11-12
SG11202110975XA (en) 2021-10-28
MX2021011913A (es) 2021-12-15

Similar Documents

Publication Publication Date Title
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
AR118273A2 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
PE20140646A1 (es) Vacuna de virus de dengue inactivado
CL2020002252A1 (es) Formulación oftálmica.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária
AR121292A1 (es) Vacuna contra hpv
CL2020001463A1 (es) Formulaciones de composiciones de vacuna contra el virus del dengue.
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
SG10201909051QA (en) Compositions and methods for live, attenuated alphavirus formulations
MX2019012620A (es) Composiciones de vacunas.
CR20170280A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
AR109291A1 (es) Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo
BR112014023398A2 (pt) vírus da doença de marek modidicado e vacinas feitas do mesmo
BR112022008711A2 (pt) Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
PE20221108A1 (es) Composicion oftalmica de bevacizumab
PE20211141A1 (es) Salmonella enteritidis recombinante y su uso como vacuna porcina
PE20212322A1 (es) Vacuna de influenza atenuada en vivo composicion y proceso de preparacion de los mismos
AR118202A1 (es) Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso